Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000500565 | SCV000594958 | pathogenic | Maturity-onset diabetes of the young type 2 | 2016-02-01 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV002376921 | SCV002605122 | likely risk allele | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Potent mutations in GCK gene is associated with poor secretion of insulin. Its associated with milder forms of diabetes, which can be controlled by diet . However, there is no sufficient evidence to ascertain the significance of rs1554334886 in MODY, yet. | |
Ambry Genetics | RCV002376921 | SCV002685023 | uncertain significance | Maturity onset diabetes mellitus in young | 2019-03-22 | criteria provided, single submitter | clinical testing | The p.L314P variant (also known as c.941T>C), located in coding exon 8 of the GCK gene, results from a T to C substitution at nucleotide position 941. The leucine at codon 314 is replaced by proline, an amino acid with similar properties. This variant was identified in one individual with a clinical diagnosis of maturity-onset diabetes of the young (Garin I et al. Clin. Endocrinol. (Oxf), 2008 Jun;68:873-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on available evidence to date, the clinical significance of this alteration remains unclear. |